Leonurine Promotes Cisplatin Sensitivity in Human Cervical Cancer Cells Through Increasing Apoptosis and Inhibiting Drug-Resistant Proteins

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• China: Human Papillomavirus and Related Cancers, Fact Sheet 2019. ICO/IARC Information Centre on HPV and Cancer; 2019.
   Google Scholar
• ZhuH, ChenA, LiS, et al. Predictive role of galectin-1 and integrin alpha5beta1 in cisplatin-based neoadjuvant chemotherapy of bulky squamous cervical cancer. Biosci Rep. 2017;37:5. doi:10.1042/BSR20170958
   Web of Science ®Google Scholar
• ChenX, ZouH, LiH, et al. Weekly versus triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of cervical cancer: a meta-analysis. Int J Gynecol Cancer. 2017;27(2):344–349.27984377
   PubMed Web of Science ®Google Scholar
• PetrelliF, De StefaniA, RaspagliesiF, LorussoD, BarniS. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol. 2014;134(1):166–171.24793000
   PubMed Web of Science ®Google Scholar
• ZhuH, LuoH, ZhangW, ShenZ, HuX, ZhuX. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885–1895.
   PubMed Web of Science ®Google Scholar
• ZhangRH, LiuZK, YangDS, ZhangXJ, SunHD, XiaoWL. Phytochemistry and pharmacology of the genus Leonurus: the herb to benefit the mothers and more. Phytochemistry. 2018;147:167–183.29335190
   PubMed Web of Science ®Google Scholar
• ZhuYZ, WuW, ZhuQ, LiuX. Discovery of Leonuri and therapeutical applications: from bench to bedside. Pharmacol Ther. 2018;188:26–35.29360539
   PubMed Web of Science ®Google Scholar
• MiaoLL, ZhouQM, PengC, LiuZH, XiongL. Leonurus japonicus (Chinese motherwort), an excellent traditional medicine for obstetrical and gynecological diseases: a comprehensive overview. Biomed Pharmacother. 2019;117:109060.31195353
   PubMed Web of Science ®Google Scholar
• SitarekP, RijoP, GarciaC, et al. Antibacterial, anti-inflammatory, antioxidant, and antiproliferative properties of essential oils from hairy and normal roots of Leonurus sibiricus L. and their chemical composition. Oxid Med Cell Longev. 2017;2017:7384061. doi:10.1155/2017/738406128191277
   PubMed Web of Science ®Google Scholar
• SermukhamedovaOV, SakipovaZB, TernynkoII, GemedzhievaNG. Representatives of Motherwort Genus (Leonurus Spp.): aspects of pharmacognostic features and relevance of new species application. Acta Pol Pharm. 2017;74(1):31–40.29474759
   PubMed Web of Science ®Google Scholar
• ChenC, ZhuZ, HuN, LiangX, HuangW. Leonurine hydrochloride suppresses inflammatory responses and ameliorates cartilage degradation in osteoarthritis via NF-kappaB signaling pathway. Inflammation. 2019.
   Web of Science ®Google Scholar
• MaoF, ZhangL, CaiMH, GuoH, YuanHH. Leonurine hydrochloride induces apoptosis of H292 lung cancer cell by a mitochondria-dependent pathway. Pharm Biol. 2015;53(11):1684–1690. doi:10.3109/13880209.2014.100140625856714
   PubMed Web of Science ®Google Scholar
• SitarekP, SkalaE, TomaM, et al. Transformed root extract of leonurus sibiricus induces apoptosis through intrinsic and extrinsic pathways in various grades of human glioma cells. Pathol Oncol Res. 2017;23(3):679–687. doi:10.1007/s12253-016-0170-628032310
   PubMed Web of Science ®Google Scholar
• SitarekP, SkalaE, TomaM, et al. A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L. Tumour Biol. 2016;37(7):8753–8764. doi:10.1007/s13277-015-4714-226743778
   PubMedGoogle Scholar
• ChouTC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.1016968952
   PubMed Web of Science ®Google Scholar
• ChouTC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-194720068163
   PubMed Web of Science ®Google Scholar
• TongZ, MejiaA, VeerankiO, et al. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol. 2019;11:1758835919864850. doi:10.1177/175883591986485031384313
   PubMed Web of Science ®Google Scholar
• CullenKJ, YangZ, SchumakerL, GuoZ. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr. 2007;39(1):43–50. doi:10.1007/s10863-006-9059-517318397
   PubMed Web of Science ®Google Scholar
• WeiX, ZhouY, QiuJ, WangX, XiaY, SuiL. Low expression of TUG1 promotes cisplatin sensitivity in cervical cancer by activating the MAPK pathway. J BUON. 2019;24(3):1020–1026.31424656
   PubMed Web of Science ®Google Scholar
• ParienteR, ParienteJA, RodriguezAB, EspinoJ. Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation. J Pineal Res. 2016;60(1):55–64. doi:10.1111/jpi.1228826462739
   PubMed Web of Science ®Google Scholar
• ChenJ, SolomidesC, ParekhH, SimpkinsF, SimpkinsH. Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol. 2015;75(6):1217–1227. doi:10.1007/s00280-015-2739-225894720
   PubMed Web of Science ®Google Scholar
• GuoQ, CaoH, QiX, et al. Research progress in reversal of tumor multi-drug resistance via natural products. Anticancer Agents Med Chem. 2017;17(11):1466–1476. doi:10.2174/187152061766617101610570429034843
   PubMed Web of Science ®Google Scholar
• HillBT, MoranE, EtievantC, et al. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. Anticancer Drugs. 2000;11(3):193–200. doi:10.1097/00001813-200003000-0000710831278
   PubMed Web of Science ®Google Scholar
• TadaY, WadaM, MigitaT, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer. 2002;98(4):630–635. doi:10.1002/ijc.1024611920626
   PubMed Web of Science ®Google Scholar
• Sedlakova I, Laco J, Caltova K, et al. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer. Int J Gynecol Cancer 2015;25(2):236–243.
   Google Scholar
• SedlakovaI, LacoJ, TosnerJ, SpacekJ. [Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients]. Ceska gynekologie. 2015;80(6):405–413.26741154
   PubMedGoogle Scholar
• SmulsonME, Simbulan-RosenthalCM, BoularesAH, et al. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul. 2000;40:183–215. doi:10.1016/S0065-2571(99)00024-210828352
   PubMedGoogle Scholar
• AlmahliH, HadchityE, JaballahMY, et al. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. Bioorg Chem. 2018;77:443–456. doi:10.1016/j.bioorg.2018.01.03429453076
   PubMed Web of Science ®Google Scholar
• WuJ, XiaoS, YuanM, et al. PARP inhibitor resensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis. Mol Med Rep. 2019;19(1):75–84. doi:10.3892/mmr.2018.962830431088
   PubMed Web of Science ®Google Scholar
• Pena-BlancoA, Garcia-SaezAJ. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 2018;285(3):416–431. doi:10.1111/febs.1418628755482
   PubMed Web of Science ®Google Scholar
• SzakacsG, PatersonJK, LudwigJA, Booth-GentheC, GottesmanMM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–234. doi:10.1038/nrd198416518375
   PubMed Web of Science ®Google Scholar
• XueC, WangC, LiuQ, et al. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Tumour Biol. 2016;37(7):8587–8597. doi:10.1007/s13277-015-4478-826733176
   PubMedGoogle Scholar
• KathawalaRJ, GuptaP, AshbyCR Jr., ChenZ-S. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1–17. doi:10.1016/j.drup.2014.11.00225554624
   PubMed Web of Science ®Google Scholar
• AbdallahHM, Al-AbdAM, El-DineRS, El-HalawanyAM. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J Adv Res. 2015;6(1):45–62. doi:10.1016/j.jare.2014.11.00825685543
   PubMed Web of Science ®Google Scholar
• KoboriT, HaradaS, NakamotoK, TokuyamaS. Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs. J Pharmacol Sci. 2014;125(3):242–254. doi:10.1254/jphs.14R01CR24989947
   PubMed Web of Science ®Google Scholar
• LuJF, PokharelD, BebawyM. MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 2015;47(4):406–419.26541366
   PubMed Web of Science ®Google Scholar
• HuP, WongPT, ZhouQ, et al. Clinical relevance of the multidrug resistance-associated protein 1 gene in nonsmall cell lung cancer: A systematic review and metaanalysis. Oncol Rep. 2018;40(5):3078–3091.30132569
   PubMed Web of Science ®Google Scholar